Galenica AG Sustains Strong Growth Trajectory in First Half 2026
Galenica AG, the Swiss retail pharmacy chain listed on the SIX Swiss Exchange, has confirmed that it has met its own growth targets for the first half of 2026 and reaffirmed its outlook for the full fiscal year. The company reported a 7.1 % increase in sales and a corresponding 7.1 % rise in adjusted EBIT, bringing first‑half revenue to CHF 2 136.5 million and adjusted EBIT to CHF 117.7 million. After adjusting for one‑off items from the prior year, the EBIT growth translates into a 12.6 % rise, underscoring the firm’s resilient profitability.
Key Drivers of Performance
Home Care and Diagnostics The expansion of the Home Care segment and the rapid uptake of diagnostic services continue to underpin Galenica’s growth. Both areas have emerged as pivotal drivers, contributing significantly to the revenue surge and the solid EBIT margin.
Pharmaceutical Wholesaling (Galexis) Galexis, the company’s wholesale division, remains on a growth path, benefiting from the increasing demand for pharmaceutical products across Switzerland. The wholesale channel’s performance complements the retail arm, providing a balanced revenue mix.
Continued Demand for In‑Pharmacy Health Services The sustained rise in demand for health‑related services offered within pharmacy premises bolsters the company’s overall service revenue and enhances customer loyalty.
Financial Snapshot
| Metric | First Half 2026 | Change vs. FY 2025 | FY 2026 Guidance |
|---|---|---|---|
| Revenue | CHF 2 136.5 M | +7.1 % | Confirmed |
| Adjusted EBIT | CHF 117.7 M | +7.1 % | Confirmed |
| EBIT (adjusted for prior‑year one‑offs) | – | +12.6 % | – |
| P/E Ratio | 23.25 | – | – |
The company’s market capitalization stands at CHF 4.24 billion, with a share price of CHF 84.65 as of 4 August 2026. The 52‑week trading range remains between CHF 81.10 and CHF 103.00, reflecting a robust market position.
Outlook and Strategic Positioning
Galenica’s management has reiterated confidence in its 2026 guidance, citing the continued expansion of high‑margin segments such as Home Care and Diagnostics. The firm’s strategic focus on integrating digital health solutions and strengthening its wholesale capabilities positions it to capture evolving consumer preferences in the Swiss healthcare market.
With a clear trajectory of consistent growth and a diversified service portfolio, Galenica AG continues to deliver solid value to shareholders while reinforcing its leadership in Switzerland’s health‑care retail sector.
